Glucose-Dependent Spatial and Temporal Modulation of Oligodendrocyte Progenitor Cell Proliferation via ACLY-Regulated Histone Acetylation

Why It Matters

By tying glucose metabolism to epigenetic control of OPC growth, the work opens avenues to modulate myelination in diseases like multiple sclerosis. Targeting ACLY could fine‑tune progenitor proliferation without systemic metabolic disruption.

Key Takeaways

• ACLY converts glucose‑derived citrate into acetyl‑CoA for histone acetylation
• High glucose elevates H3K27ac at OPC proliferation genes
• ACLY knockout suppresses glucose‑induced OPC division
• Spatially distinct OPC responses observed across cortex and white matter

Pulse Analysis

The discovery that glucose metabolism fuels oligodendrocyte progenitor cell (OPC) proliferation via ACLY‑driven histone acetylation adds a crucial layer to our understanding of brain development. Metabolic substrates have long been recognized as energy sources, but this study demonstrates that citrate‑derived acetyl‑CoA directly fuels epigenetic modifications that switch on cell‑cycle genes. By integrating bulk RNA‑seq, single‑cell transcriptomics, and quantitative histone mass‑spectrometry, the researchers mapped a clear pathway: elevated extracellular glucose boosts ACLY activity, raises nuclear acetyl‑CoA, and enriches H3K27ac at promoters of proliferation drivers such as Cyclin D1 and E2F1. This mechanistic link explains why OPCs proliferate more robustly in glucose‑rich niches, offering a metabolic‑epigenetic axis that can be pharmacologically targeted.

Beyond basic biology, the findings have immediate translational relevance for demyelinating diseases. In multiple sclerosis, remyelination failure often stems from insufficient OPC recruitment and differentiation. Modulating ACLY activity could amplify OPC pools in lesion‑adjacent regions, enhancing the intrinsic repair capacity without the systemic side effects of broad metabolic interventions. Moreover, the spatial and temporal heterogeneity uncovered—where cortical OPCs respond differently than those in deep white matter—suggests that region‑specific dosing strategies may be required for optimal therapeutic outcomes.

Future research will likely explore ACLY inhibitors or activators in animal models of demyelination, assess long‑term safety, and investigate how other metabolic pathways intersect with epigenetic regulators in glial cells. The study also raises broader questions about how diet‑derived glucose fluctuations influence brain plasticity throughout life. As the field moves toward precision neuro‑metabolism, the ACLY‑histone acetylation axis stands out as a promising target for boosting myelin repair and preserving neural function.